Business Context and Reporting Period
This Form 6-K filing reports the results of the Annual General Meeting (AGM) of Hong Kong Pharma Digital Technology Holdings Limited (the "Company"), held on December 12, 2025. The filing was submitted on December 17, 2025. The Company is a foreign private issuer with its principal executive office in Hong Kong. The AGM addressed nine proposals, all of which were approved by shareholders.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance actions and capital structure changes approved at the AGM.
Material Changes and Corporate Actions
- Board Re-election: Shareholders re-elected five directors: Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, and Dr. Kam Leung Chan.
- Authorized Capital Increase: Authorized share capital increased from US$100,000 (100,000,000 shares) to US$1,000,000 (1,000,000,000 shares).
- Share Class Restructuring: The Company created two classes of shares:
- Class A Ordinary Shares: 940,000,000 authorized; 1 vote per share. Existing shares were re-designated to this class.
- Class B Ordinary Shares: 60,000,000 authorized; 50 votes per share.
- Reverse Share Split: Shareholders authorized a reverse share split and consolidation at a ratio between 1-for-10 and 1-for-100, to be determined by the Board. This will reduce the number of shares and increase par value proportionally.
- Name Change: The Company's English name changed from "Hong Kong Pharma Digital Technology Holdings Limited" to "Cellyan Biotechnology Co., Ltd".
- Share Repurchase and Issuance: The Company approved the repurchase of 7,150,000 Class A shares from TUTU Business Services Limited for a nominal price of US$1. This will be funded by issuing 7,150,000 new Class B shares, leaving total issued share capital unchanged.
- Equity Incentive Plan: The 2025 Equity Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The primary risks implied by the corporate actions include the dilution of voting power for Class A shareholders due to the creation of high-vote Class B shares and the potential impact of the reverse share split on share liquidity and market price.
Investor Verification Checklist
- Verify the exact reverse share split ratio to be determined by the Board (range: 1-for-10 to 1-for-100).
- Confirm the effective date of the name change to "Cellyan Biotechnology Co., Ltd" upon receipt of the Certificate of Incorporation.
- Review the impact of the 50-vote Class B shares on future control and voting dynamics.
- Monitor the implementation of the share repurchase from TUTU Business Services Limited and the corresponding issuance of Class B shares.
- Check for subsequent filings detailing the specific terms of the 2025 Equity Incentive Plan.